Schering-Plough announces Pfizer closing
Schering-Plough has announced the successful closing
of its previously announced transaction with Pfizer Animal Health, to divest
certain animal health products from selected franchises in the European Economic
Area to Pfizer.
With this announcement, Schering-Plough has now
successfully completed all product divestments required by the commitments made
to the European Commission in connection with its approval of its acquisition of
Organon Biosciences in 2007.
Transaction an important step
"We are making good progress both globally
and at the country level on our integration, and the closing of the transaction
with Pfizer is another very important step in both that process, as well as
fulfilling our acquisition-related commitments to the European Commission," said
Ruurd Stolp, President of Intervet/Schering-Plough Animal Health.
Europe, Pfizer acquired products from the parasiticide, swine E. coli vaccine,
ruminant clostridia vaccine, equine influenza vaccine, ruminant neonatal
vaccine, anti-inflammatory, companion animal/insulin and companion
animal/euthanasia, and rabies vaccine franchises of Intervet/Schering-Plough
Animal Health. This agreement does not affect Intervet/Schering-Plough Animal
Health's marketing of these products in other global markets beyond
Click here for the free Pig Progress
To comment, login here
Or register to be able to comment.